Show simple item record

dc.contributor.authorKefelioglu, Haluk
dc.contributor.authorSekeroglu, Zulal Atli
dc.contributor.authorCosguner, Gamze
dc.contributor.authorYedier, Seval Kontas
dc.contributor.authorSekeroglu, Vedat
dc.date.accessioned2020-06-21T13:27:38Z
dc.date.available2020-06-21T13:27:38Z
dc.date.issued2017
dc.identifier.issn0148-0545
dc.identifier.issn1525-6014
dc.identifier.urihttps://doi.org/10.1080/01480545.2016.1252920
dc.identifier.urihttps://hdl.handle.net/20.500.12712/12822
dc.descriptionWOS: 000406544200008en_US
dc.descriptionPubMed: 27894189en_US
dc.description.abstractIt has been stated that some antipsychotic drugs might cause genotoxic and carcinogenic effects. Ziprasidone (ZIP) is commonly used an antipsychotic drug. However, its genotoxicity and carcinogenicity data are very limited. The cytotoxicity and genotoxicity of ZIP on human peripheral blood lymphocytes were examined in vitro by sister chromatid exchange (SCE), chromosome aberration (CA) and micronucleus (MN) tests in this study. Lymphocyte cultures were treated with 50, 75 and 100 mg/ml of ZIP in the presence and absence of a metabolic activator (S9 mix). Dimethylsulfoxide was used as a solvent control. While the cells were treated with ZIP for 24 h and 48 h in cultures without S9 mix, the cultures with S9 mix were exposed to ZIP for 3 h. ZIP and its metabolites can exert cytotoxic activities due to significant decreases in mitotic index, proliferation index and nuclear division index in the presence and absence of S9 mix. Statistically significant increases in CAs, aberrant cells and MN values in the presence and absence of S9 mix were found in cultures treated with ZIP. While ZIP significantly increased the SCE values in the absence of S9 mix at all concentrations, increased SCE values in cultures with S9 mix were not found to significantly at all concentrations tested. Our results indicated that both ZIP and its metabolites have cytotoxic, cytostatic and genotoxic potential on lymphocyte cultures under the experimental conditions. Further studies are necessary to make a possible risk assessment in patients receiving therapy with this drug.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)en_US
dc.description.sponsorshipWe would like to thank to The Scientific and Technological Research Council of Turkey (TUBITAK) for the financial support of this work.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.isversionof10.1080/01480545.2016.1252920en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectZiprasidoneen_US
dc.subjectmetabolic activationen_US
dc.subjectcytotoxicityen_US
dc.subjectchromosome aberrationen_US
dc.subjectmicronucleusen_US
dc.subjectsister chromatid exchangeen_US
dc.subjectlymphocytesen_US
dc.titleZiprasidone induces cytotoxicity and genotoxicity in human peripheral lymphocytesen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume40en_US
dc.identifier.issue4en_US
dc.identifier.startpage425en_US
dc.identifier.endpage431en_US
dc.relation.journalDrug and Chemical Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record